Drugs / P140K-MGMT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05052957 | Jan 2023 → Nov 2026 expected | adult glioblastoma, gliosarcoma | Leland Metheny | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P140K-MGMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05052957 ↗ |
| Modality | Cell therapy | “Ex Vivo Cultured P140K MGMT CD34+ Cells.” NCT05052957 ↗ |
| Target | MGMT | “Placing P140K MGMT, a gene that has been created in the laboratory into bone marrow making the bone more resistant to chemotherapy” NCT05052957 ↗ |